MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab

NCT04120753 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2024-07-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg, 20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.

Conditions

Interventions

DRUG

OLOMAX 20/5/5mg

Tablets, Oral, QD

DRUG

OLOMAX 20/5/10mg

Tablets, Oral, QD

DRUG

Olmesartan 20 mg/Amlodipine 5 mg

Tablets, Oral, QD

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Inho Chae · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-07-06
Completion
2021-07-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120753 on ClinicalTrials.gov